-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, CcphaDAJPgDmI9XXOXLR0vq0pBQBwDqjZF+b3tdjAuR8DX11MIAdFH/EZY0LzP60 dmtpih0URxqT9cOdEatXZg== 0000921895-04-001608.txt : 20041013 0000921895-04-001608.hdr.sgml : 20041013 20041013171149 ACCESSION NUMBER: 0000921895-04-001608 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20040913 ITEM INFORMATION: Material Impairments FILED AS OF DATE: 20041013 DATE AS OF CHANGE: 20041013 FILER: COMPANY DATA: COMPANY CONFORMED NAME: QUIGLEY CORP CENTRAL INDEX KEY: 0000868278 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 232577138 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-21617 FILM NUMBER: 041077513 BUSINESS ADDRESS: STREET 1: KELLS BUILDING STREET 2: 621 SHADY RETREAT RD CITY: DOYLESTOWN STATE: PA ZIP: 18901 BUSINESS PHONE: 2153450919 MAIL ADDRESS: STREET 1: PO BOX 1349 STREET 2: LANDMARK BLDG, 10 S CLINTON ST CITY: DOYLESTOWN STATE: PA ZIP: 18901 8-K 1 form8k03814_09132004.htm 8-K sec document 



                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                              WASHINGTON, DC 20549


                                    FORM 8-K


                                 CURRENT REPORT
                     PURSUANT TO SECTION 13 OR 15(d) OF THE
                         SECURITIES EXCHANGE ACT OF 1934

       Date of Report (Date of earliest event reported) September 13, 2004
                                                        ------------------

                              --------------------

                             THE QUIGLEY CORPORATION
                             -----------------------
               (Exact Name of Registrant as Specified in Charter)


     Nevada                            0-21617                  23-2577138
     ------                            -------                  ----------
(State or Other Jurisdiction          (Commission            (IRS Employer
        of Incorporation)             File Number)           Identification No.)


 Kells Building, 621 Shady Retreat Road, P.O. Box 1349, Doylestown, PA  18901
 ----------------------------------------------------------------------------
             (Address of Principal Executive Offices)                 (Zip Code)


        Registrant's telephone number, including area code (215) 345-0919
                                                           --------------
                                       N/A
          -------------------------------------------------------------
          (Former Name or Former Address, if Changed Since Last Report)


     Check the  appropriate  box below if the Form 8-K  filing  is  intended  to
simultaneously  satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

     |_| Written  communications  pursuant to Rule 425 under the  Securities Act
(17 CFR 230.425)

     |_| Soliciting  material pursuant to Rule 14a-12 under the Exchange Act (17
CFR 240.14a-12)

     |_|  Pre-commencement  communications  pursuant to Rule 14d-2(b)  under the
Exchange Act (17 CFR 240.14d-2(b))

     |_|  Pre-commencement  communications  pursuant to Rule 13e-4(c)  under the
Exchange Act (17 CFR 240.13e-4(c))





ITEM 2.06    MATERIAL IMPAIRMENTS.

     On September 13, 2004, The Quigley Corporation (the "Company") notified its
customers  of its decision to  discontinue  the  Cold-EEZE(R)  Cold Remedy Nasal
Spray  product  within our line of cold remedy  products.  The decision was made
because  the product has not  developed  into a viable  entry in the nasal spray
cold remedy category.  Since its launch  approximately one year ago, the product
has not met either the Company's sales  expectations or its return on investment
projections.  Based on the Company's preliminary estimates,  the discontinuation
of the nasal spray product will result in an approximately $422,000 write-off of
inventory  and an  approximately  $974,000  charge to net sales  resulting  from
anticipated  customer  returns of the product.  As a result of all charges,  the
Company's  results  for  the  third  quarter  will  be  adversely   impacted  by
approximately  $1,361,000.  At this time,  the Company does not  anticipate  any
additional future charges.





                                   SIGNATURES

     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.



                                             THE QUIGLEY CORPORATION
                                                    (Registrant)

Date: October 13, 2004
                                             By: /s/ George J. Longo
                                                -------------------------------
                                                Name:   George J. Longo
                                                Title:  Vice President and Chief
                                                        Financial Officer
-----END PRIVACY-ENHANCED MESSAGE-----